Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (98)	10/2/1998 5:09:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1475

>> Sometime in the next several months, more likely In January of next year after tax loss selling, a lot of these biotechs will "melt up" as people re-establish positions. << Not even 12/94 came close to this. I have never seen so many companies that could 4X on modest news. BTRN is particularly frustrating. We probably won't see AlloMune partnered until '99 (if at all), so major news in the interim should be restricted to patents, early MEDI clinical results, preclinical models, etc. However, you have (1) Novartis watching them trade at a MC which is a fraction of what they will pay to access the XenoMune program, and (2) MEDI watching them trade at a MC which represents only a couple of months of the royalties that they hope to pay on 507. What are the benefits of being a public company?? This is absurd. I'll take the opportunity, but it sure has been ugly and painful.